Bitte benutzen Sie diese Kennung, um auf die Ressource zu verweisen:
https://doi.org/10.21256/zhaw-19484| Publikationstyp: | Beitrag in wissenschaftlicher Zeitschrift |
| Art der Begutachtung: | Peer review (Publikation) |
| Titel: | Inhibitory antibodies designed for matrix metalloproteinase modulation |
| Autor/-in: | Fischer, Thomas Riedl, Rainer |
| et. al: | No |
| DOI: | 10.3390/molecules24122265 10.21256/zhaw-19484 |
| Erschienen in: | Molecules |
| Band(Heft): | 24 |
| Heft: | 12 |
| Seite(n): | 2265 |
| Erscheinungsdatum: | 2019 |
| Verlag / Hrsg. Institution: | MDPI |
| ISSN: | 1420-3049 1433-1373 |
| Sprache: | Englisch |
| Schlagwörter: | Drug design; Inhibitory antibody; Matrix metalloproteinase; Selectivity; Tissue inhibitors of metalloproteinase; Amino acid sequence; Animal; Monoclonal antibody; Binding site; Human; Matrix metalloproteinase inhibitors; Molecular conformation; Molecular docking simulation; Molecular dynamics simulation; Protein binding; Structure-activity relationship |
| Fachgebiet (DDC): | 571: Physiologie und verwandte Themen |
| Zusammenfassung: | The family of matrix metalloproteinases (MMPs) consists of a set of biological targets that are involved in a multitude of severe pathogenic events such as different forms of cancers or arthritis. Modulation of the target class with small molecule drugs has not led to the anticipated success until present, as all clinical trials failed due to unacceptable side effects or a lack of therapeutic outcome. Monoclonal antibodies offer a tremendous therapeutic potential given their high target selectivity and good pharmacokinetic profiles. For the treatment of a variety of diseases there are already antibody therapies available and the number is increasing. Recently, several antibodies were developed for the selective inhibition of single MMPs that showed high potency and were therefore investigated in in vivo studies with promising results. In this review, we highlight the progress that has been achieved toward the design of inhibitory antibodies that successfully modulate MMP-9 and MMP-14. |
| URI: | https://digitalcollection.zhaw.ch/handle/11475/19484 |
| Volltext Version: | Publizierte Version |
| Lizenz (gemäss Verlagsvertrag): | CC BY 4.0: Namensnennung 4.0 International |
| Departement: | Life Sciences und Facility Management |
| Enthalten in den Sammlungen: | Publikationen Life Sciences und Facility Management |
Dateien zu dieser Ressource:
| Datei | Beschreibung | Größe | Format | |
|---|---|---|---|---|
| 2019_Fischer_Inhibitory-antibodies.pdf | 2.82 MB | Adobe PDF |  Öffnen/Anzeigen |
Zur Langanzeige
Fischer, T., & Riedl, R. (2019). Inhibitory antibodies designed for matrix metalloproteinase modulation. Molecules, 24(12), 2265. https://doi.org/10.3390/molecules24122265
Fischer, T. and Riedl, R. (2019) ‘Inhibitory antibodies designed for matrix metalloproteinase modulation’, Molecules, 24(12), p. 2265. Available at: https://doi.org/10.3390/molecules24122265.
T. Fischer and R. Riedl, “Inhibitory antibodies designed for matrix metalloproteinase modulation,” Molecules, vol. 24, no. 12, p. 2265, 2019, doi: 10.3390/molecules24122265.
FISCHER, Thomas und Rainer RIEDL, 2019. Inhibitory antibodies designed for matrix metalloproteinase modulation. Molecules. 2019. Bd. 24, Nr. 12, S. 2265. DOI 10.3390/molecules24122265
Fischer, Thomas, and Rainer Riedl. 2019. “Inhibitory Antibodies Designed for Matrix Metalloproteinase Modulation.” Molecules 24 (12): 2265. https://doi.org/10.3390/molecules24122265.
Fischer, Thomas, and Rainer Riedl. “Inhibitory Antibodies Designed for Matrix Metalloproteinase Modulation.” Molecules, vol. 24, no. 12, 2019, p. 2265, https://doi.org/10.3390/molecules24122265.
Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt, soweit nicht anderweitig angezeigt.